Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases

Brain metastases are the most common cause of death in patients with metastatic melanoma, and the RAF-MEK-ERK and PI3K-AKT signaling pathways are key players in melanoma progression and drug resistance. The BRAF inhibitor vemurafenib significantly improved overall survival. However, brain metastases...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Niessner, Heike, Forschner, Andrea, Klumpp, Bernhard, Honegger, Jürgen B., Witte, Maria, Bornemann, Antje, Dummer, Reinhard, Adam, Annemarie, Bauer, Jürgen, Tabatabai, Ghazaleh, Flaherty, Keith, Sinnberg, Tobias, Beck, Daniela, Leiter, Ulrike, Mauch, Cornelia, Roesch, Alexander, Weide, Benjamin, Eigentler, Thomas, Schadendorf, Dirk, Garbe, Claus, Kulms, Dagmar, Quintanilla-Martinez, Leticia, Meier, Friedegund
Format: Artigo
Jezik:Inglês
Izdano: Blackwell Publishing Ltd 2013
Teme:
Clinical Cancer Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3797558/
https://ncbi.nlm.nih.gov/pubmed/24133630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.50
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items